Dentsply Sirona Stock Gains 0.96% Despite Underperformance Compared to Competitors
June 15, 2023
☀️Trending News
Dentsply Sirona ($NASDAQ:XRAY) Inc., a global leader in dental and medical technologies, saw its stock rise 0.96% on Tuesday to $39.07, despite the generally positive performance of the stock market. Unfortunately, this was an underperformance compared to its competitors, some of which had double-digit returns. The company is one of the largest dental and medical technology manufacturers in the world, with a wide range of products from dental handpieces to advanced imaging systems. Dentsply Sirona’s products are used in both the dental and medical industries, with their offerings serving to improve healthcare for millions of patients worldwide.
Despite this, the stock took a hit on Tuesday, closing at a 0.96% gain, which was lower compared to other competitors on the stock market. While its performance on Tuesday may have been lackluster, Dentsply Sirona Inc. is well-positioned to continue outperforming its competitors in the coming years. With its diverse and innovative product offerings, the company is sure to remain a leader in the dental and medical technology space.
Analysis
At GoodWhale, we have performed an analysis of DENTSPLY SIRONA‘s fundamentals. According to our Star Chart, this company has a high health score of 7/10, considering its cashflows and debt. This indicates that it is capable to safely ride out any crisis without the risk of bankruptcy. We also found that DENTSPLY SIRONA is strong in dividend, profitability, and weak in asset growth. Based on these results, we classified DENTSPLY SIRONA as a ‘cow’, which is a type of company that has the track record of paying out consistent and sustainable dividends. Given its high health score and reliable dividend payments, we believe that this company may be of interest to income-seeking investors. Those looking for a stable investment with reliable returns may find an attractive opportunity here. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dentsply Sirona. More…
| Total Revenues | Net Income | Net Margin |
| 3.93k | -1.04k | 4.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dentsply Sirona. More…
| Operations | Investing | Financing |
| 403 | -132 | -302 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dentsply Sirona. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.67k | 4.04k | 17.14 |
Key Ratios Snapshot
Some of the financial key ratios for Dentsply Sirona are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -0.2% | -10.5% | -28.1% |
| FCF Margin | ROE | ROA |
| 6.6% | -18.5% | -9.0% |
Peers
In the competitive world of dental equipment manufacturers, Dentsply Sirona Inc. has held its own against some tough competitors. Edwards Lifesciences Corp, Escalon Medical Corp, and Medistim ASA are all companies that produce dental equipment and supplies that compete with Dentsply Sirona Inc.
– Edwards Lifesciences Corp ($NYSE:EW)
Edwards Lifesciences Corp is a medical technology company that specializes in products and technologies for the treatment of cardiovascular diseases. The company’s market capitalization is $45.45 billion as of 2022, and its return on equity is 18.9%. Edwards Lifesciences is headquartered in Irvine, California, and has operations in more than 75 countries worldwide.
– Escalon Medical Corp ($OTCPK:ESMC)
Escalon Medical Corp is a medical device company that manufactures and markets products for the ophthalmology, optometry, and veterinary markets worldwide. It has a market cap of 800.11k as of 2022 and a return on equity of 1.57%. The company’s products include ophthalmic surgical instruments, intraocular lenses, contact lenses, and disposables.
– Medistim ASA ($BER:MD1)
Medistim ASA is a Norwegian medical device company that develops, manufactures, and markets products for use in cardiac and vascular surgery. The company has a market capitalization of 455.95 million as of 2022 and a return on equity of 24.86%. Medistim’s products are used in a variety of procedures, including coronary artery bypass graft surgery, valve replacement surgery, and endovascular surgery. The company’s products are sold in over 50 countries worldwide.
Summary
Dentsply Sirona Inc. shares experienced mixed performance on Tuesday, with a 0.96% increase in the stock price to close at $39.07, despite gains in the broader market. This can be attributed to the company’s weak performance when compared to its competitors in the dental industry. Investors should do further research before investing in this stock as it may not be the best option for long-term growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
